88 - New Anti-Infective Agents

Moderator(s)

• 

  Pranita Tamma, MD, MHS

  Associate Professor
  Johns Hopkins University School of Medicine
  Baltimore, Maryland, United States
• 

  Christopher Bland, PharmD, FCCP, FIDSA, BCPS

  Albert W. Jowdy Professor in Pharmacy Care
  Pharmacy
  University of Georgia College of Pharmacy
  Savannah, GA, United States

Presentations:

• 3:15 PM - 3:27 PM US ET

  A Novel SARS-CoV-2 mRNA Virus-Like Particle Vaccine is Highly Potent and Well Tolerated in Adults in a Phase I Randomized Clinical Trial
  

  Presenting Author: Tope Oyedele, MD (he/him/his) – AstraZeneca

  Co-Author: Rachel Park, PharmD – AstraZeneca

  Co-Author: Kelly Morales, n/a – Coastal Carolina Research Center

  Co-Author: Manish Jain, MD – Flourish - Great Lakes Clinical Trials

  Co-Author: Lawrence Sher, MD – Peninsula Research Associates

  Co-Author: Apinya Vutikullird, MD – Ark Clinical Research

  Co-Author: Thomas Klein, MD – Alliance for Multispecialty Research

  Co-Author: Abby Isaacs, n/a – AstraZeneca

  Co-Author: Kathryn Shoemaker, MS – Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA

  Co-Author: Ann Marie Stanley, PhD – Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA

  Co-Author: Joseph Lee, MSc – AstraZeneca

  Co-Author: Cindy Handelsman, BSc – AstraZeneca

  Co-Author: Stacey Cromer Berman, PhD – AstraZeneca

  Presenting Author: Lee-Jah Chang, MD (he/him/his) – AstraZeneca
• 3:27 PM - 3:39 PM US ET

  Lacticaseibacillus rhamnosus CRL 2244 extracts as an antimicrobial strategy against Community- and Hospital-Associated Staphylococcus aureus
  

  Co-Author: Cecilia Rodriguez, PhD – CERELA

  Co-Author: Briea Gasca, Undergraduate Student – CSUF

  Co-Author: Camila Leal, PhD Student – CERELA

  Co-Author: Nicholas Salzameda, Professor – CSUF

  Co-Author: Robert A. Bonomo, MD (he/him/his) – Case Western Reserve University/ Louis Stokes Cleveland VA Medical Center

  Presenting Author: Maria Soledad Ramirez, PhD (she/her/hers) – California State University Fullerton
• 3:39 PM - 3:51 PM US ET

  MDL-001: A Broad-Spectrum Antiviral Targeting the Thumb-1 Domain of Viral Polymerases
  

  Presenting Author: Virgil Woods, BS, MPhil, – Model Medicines

  Co-Author: Tyler Umansky, BA – Model Medicines

  Co-Author: Sean Russell, n/a – Model Medicines

  Co-Author: David Garvey, PhD – DSG Pharma Consulting, LLC

  Co-Author: David Smith, MD, MAS – University of California, San Diego

  Co-Author: Daniel Haders, PhD – Model Medicines
• 3:51 PM - 4:03 PM US ET

  Efficacy and safety results from the Phase 2 clinical trial of pritelivir versus foscarnet for treatment of acyclovir-refractory and/or resistant mucocutaneous HSV infections in immunocompromised subjects
  

  Presenting Author: Camille N. Kotton, MD, FIDSA, FAST – Massachusetts General Hospital

  Co-Author: Robin K. Avery, MD – Johns Hopkins

  Co-Author: Kimberly Workowski, MD – Department of Medicine, Emory University, Atlanta, GA, USA

  Co-Author: Princy N. Kumar, MD – Georgetown University Medical Center

  Co-Author: Joerg Albrecht, MD/PhD – Cook County Health

  Co-Author: Pranatharthi Chandrasekar, md – wayne state university

  Co-Author: Mayur Ramesh, MD – Henry Ford Hospital

  Co-Author: Anna Wald, MD, MPH – University of Washington

  Co-Author: Alexander Birkmann, PhD (he/him/his) – AiCuris Anti-Infective Cures AG

  Co-Author: Melanie E. Sumner, MSc – AiCuris Anti-infective Cures AG

  Co-Author: Bernadette Surujbally, MSc – AiCuris Anti-Infective Cures AG

  Co-Author: Cynthia Wat, MBBS MRCP MFPM – Aicuris Anti-infective Cures AG

  Co-Author: Roy F. Chemaly, MD/MPH (he/him/his) – University of Texas MD Anderson Cancer Center
• 4:03 PM - 4:15 PM US ET

  Phage Therapy with BX211 Demonstrates Positive Efficacy Results in Staphylococcus Aureus Diabetic Foot Osteomyelitis: Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial
  

  Co-Author: Benjamin A. Lipsky, MD, FACP, FIDSA, FRCP, FRCPS – University of Washington

  Presenting Author: Ariel Cohen, PhD – BiomX

  Co-Author: Siblian Boston, MSc – BiomX Inc

  Co-Author: Christine Orlando, MSc – BiomX Inc

  Co-Author: Mike Sowers, BS – BiomX Inc

  Co-Author: Joe Fackler, PhD – BiomX Inc

  Co-Author: Rima Sandhu, PhD – BiomX Inc

  Co-Author: Aravinda Vadlamudi, MS(Microbiology) – Adaptive Phage Therapeutics

  Co-Author: Rob cohen, MSc, MBA – BiomX Inc

  Co-Author: Anantha Makineni, MS in Chemistry and Biochemistry – BiomX Inc

  Co-Author: Edward Fang, MD – BiomX Inc

  Co-Author: Robert Hopkins, MD – BiomX Inc

  Co-Author: Jagoda Jablonska, PhD – BiomX, Ltd

  Co-Author: David Zlotin, Msc – BiomX Ltd

  Co-Author: Ron Mordoch, MSc – BiomX Ltd

  Co-Author: Edith Kario, PhD – BiomX, Ltd

  Co-Author: Jenia Gold, M.Sc – BiomX, Ltd

  Co-Author: Myriam Golembo, PhD – BiomX, Ltd

  Co-Author: Nitsan Halevy, MD – BiomX Ltd

  Co-Author: Hila Sberro Livnat, PhD – BiomX, Ltd

  Co-Author: Merav Bassan, PhD – MB
• 4:15 PM - 4:27 PM US ET

  EDP-323, a First-in-Class, Oral, RSV-Specific, Non-Nucleoside L-Protein Inhibitor Antiviral Rapidly Reduces Total RSV Symptoms, Lower Respiratory Tract RSV Symptoms and Viral Load After Human Viral Challenge
  

  Presenting Author: John DeVincenzo, MD – Enanta Pharmaceuticals

  Co-Author: Alaa Ahmad, PhD – Enanta Pharmaceuticals

  Co-Author: Shijie Chen, PhD – Enanta Pharmaceuticals

  Co-Author: Brandon Londt, PhD – hVivo

  Co-Author: Alexander J. Mann, BSc (Hons) – hVIVO

  Co-Author: Julie Mori, PhD – hVivo Services LTD

  Co-Author: Andrew P. Catchpole, PhD – hVivo Services Ltd.

  Co-Author: Scott T Rottinghaus, MD – Enanta Pharmaceuticals